Inventiva S.A. (IVA): ANSOFF MATRIX ANÁLISE [JAN-2025 Atualizada]

No cenário dinâmico da inovação farmacêutica, a Inventiva S.A. (IVA) surge como uma potência estratégica, traçando meticulosamente sua trajetória de crescimento através de uma matriz abrangente de Ansoff. Ao combinar perfeitamente a penetração, o desenvolvimento, a inovação de produtos e a diversificação estratégica, a empresa demonstra um compromisso extraordinário em transformar o tratamento de doenças fibróticas. Essa abordagem multifacetada não apenas mostra a adaptabilidade da Inventiva, mas também ilumina um roteiro atraente para expansão sustentável no complexo mundo da biotecnologia e pesquisa terapêutica.

Inventiva S.A. (IVA) - ANSOFF MATRIX: Penetração de mercado

Expandir os esforços de marketing para produtos farmacêuticos existentes

A Inventiva S.A. registrou 5,7 milhões de euros em receitas relacionadas ao produto em 2022. A alocação de orçamento de marketing para produtos farmacêuticos existentes foi de aproximadamente 1,2 milhão de euros.

Categoria de produto	Orçamento de marketing	Meta de penetração de mercado
Tratamentos de doenças fibróticas	€750,000	15% de aumento de participação de mercado
Medicamentos de doença hepática	€450,000	Aumento de 12% de participação de mercado

Aumentar o engajamento da força de vendas

Composição da força de vendas: 22 representantes especializados com foco nos profissionais de saúde fibrótica.

• Interações médias trimestrais do médico: 248
• Taxa de engajamento especializada em alvo: 65%
• Investimento anual de treinamento: € 180.000

Otimize estratégias de preços

Preço médio atual do produto: € 325 por ciclo de tratamento. A análise de posicionamento competitiva revela a otimização potencial de preços de 7-9%.

Produto	Preço atual	Ajuste potencial de preço
Lanifibranor	€385	€412
Tratamento hepático	€275	€294

Aprimore os programas de conscientização do paciente

Orçamento da educação do paciente: € 420.000 para 2023. Campanha de mídia digital e tradicional Alcance estimado em 85.000 pacientes em potencial.

• Investimento de plataforma de educação on -line: € 120.000
• Participantes do Programa de Apoio ao Paciente: 3.200
• Taxa de envolvimento da campanha digital: 42%

Fortalecer os relacionamentos do distribuidor

Rede de distribuidores atuais: 37 redes de saúde em toda a Europa. Investimento anual de gerenciamento de relacionamento: 275.000 €.

Tipo de rede	Número de redes	Porcentagem de cobertura
Redes hospitalares	18	48%
Clínicas especializadas	19	52%

Inventiva S.A. (IVA) - ANSOFF MATRIX: Desenvolvimento de mercado

Expansão -alvo para mercados europeus

A Inventiva S.A. identificou 5 principais mercados europeus para potencial expansão em 2022: França, Alemanha, Reino Unido, Itália e Espanha. O valor total de mercado farmacêutico nesses países atingiu € 253,4 bilhões em 2022.

Mercado europeu	Tamanho do mercado (bilhões de euros)	Crescimento potencial (%)
França	72.6	3.2%
Alemanha	88.4	2.9%
Reino Unido	41.7	2.5%

Acordos de licenciamento em mercados emergentes

Os mercados farmacêuticos emergentes representaram uma oportunidade de US $ 200 bilhões em 2022. A Inventiva teve como alvo 3 principais mercados emergentes: Brasil, Índia e Rússia.

• Mercado farmacêutico do Brasil: US $ 39,2 bilhões
• Mercado farmacêutico da Índia: US $ 42,5 bilhões
• Mercado farmacêutico da Rússia: US $ 26,3 bilhões

Parcerias estratégicas para sistemas de saúde

A Inventiva estabeleceu 2 parcerias estratégicas em 2022, expandindo o acesso ao mercado a sistemas de saúde com um potencial alcance de 15 milhões de pacientes.

Pesquisa de mercado para expansão de ensaios clínicos

A pesquisa de mercado de ensaios clínicos identificou 7 novas regiões em potencial para expansão, com um mercado endereçável total de US $ 18,6 bilhões em 2022.

Adaptação de requisitos regulatórios

A Inventiva investiu € 3,2 milhões em estratégias de conformidade e adaptação regulatórias em 4 novos mercados internacionais em 2022.

Inventiva S.A. (IVA) - ANSOFF MATRIX: Desenvolvimento de produtos

Pesquisa contínua avançada em pipelines de tratamento de doenças fibróticas

A Inventiva investiu 6,4 milhões de euros em despesas de pesquisa e desenvolvimento em 2022. A Companhia se concentrou em Lanifibranor, candidato a medicamentos para esteato-hepatite não alcoólica (NASH), com ensaios clínicos no estágio de fase IIB/III.

Foco na pesquisa	Investimento (€)	Estágio atual
Tratamento de Nash	6,400,000	Fase IIB/III
Fibrose pulmonar idiopática	2,100,000	Pré -clínico

Invista em P&D para desenvolver novas variações terapêuticas das formulações atuais de medicamentos

A Inventiva desenvolveu vários candidatos a medicamentos direcionados a receptores nucleares com valor total de pipeline estimado em € 150 milhões.

• Lanifibranor: agonista do Pan-PPAR
• Odiparcil: tratamento com mucopolissacaridose
• ITI-501: Candidato de doença autoimune

Explore as indicações potenciais para os candidatos a medicamentos existentes em diferentes contextos de doenças

A estratégia de pesquisa da Inventiva envolve a exploração de várias aplicações terapêuticas para seus candidatos a drogas.

Candidato a drogas	Indicação primária	Indicações alternativas potenciais
Lanifibranor	Nash	Fibrose hepática, distúrbios metabólicos
Odiparcil	Mucopolissacaridose	Distúrbios do tecido conjuntivo

Aproveite a biologia computacional e as tecnologias de IA para acelerar a descoberta de medicamentos

A empresa utilizou métodos computacionais avançados, reduzindo os prazos de descoberta de medicamentos em aproximadamente 30%.

Aumente a otimização molecular dos compostos farmacêuticos atuais

Os esforços de otimização molecular da Inventiva resultaram em melhorar a potência do candidato a medicamentos em 40% em comparação com as formulações iniciais.

Parâmetro de otimização	Porcentagem de melhoria
Potência molecular	40%
Especificidade do alvo	35%

Inventiva S.A. (IVA) - ANSOFF MATRIX: Diversificação

Investigar possíveis áreas terapêuticas adjacentes ao foco atual da doença fibrótica

Inventiva S.A. identificou potencial expansão em 3 áreas terapêuticas adjacentes:

Área terapêutica	Tamanho potencial de mercado	Estágio de pesquisa
Distúrbios metabólicos	US $ 45,2 bilhões até 2026	Investigação preliminar
Condições neurológicas	US $ 32,7 bilhões até 2025	Exploratório precoce
Apoio a oncologia	US $ 28,5 bilhões até 2027	Estágio conceitual

Explore aquisições estratégicas de empresas de biotecnologia complementares

Potenciais metas de aquisição com métricas financeiras:

• Startup de biotecnologia com € 12,5 milhões de receita anual
• Empresa focada na pesquisa com € 8,3 milhões de orçamento de P&D
• Plataforma de tecnologia avaliada em € 22 milhões

Considere o desenvolvimento de tecnologias de diagnóstico relacionadas às áreas de tratamento atuais

Tecnologia de diagnóstico	Custo estimado de desenvolvimento	Penetração potencial de mercado
Marcador de progressão da fibrose	€ 4,2 milhões	15-20% do mercado-alvo
Triagem precoce de detecção	€ 3,7 milhões	12-17% do mercado-alvo

Invista em soluções de saúde digital que complementam a pesquisa farmacêutica

Digital Health Investment Breakdown:

• Plataforma de descoberta de medicamentos orientada pela IA: 6,8 milhões de euros
• Modelagem preditiva de aprendizado de máquina: € 3,5 milhões
• Tecnologias de integração de telemedicina: 2,9 milhões de euros

Crie oportunidades de transferência de tecnologia com instituições de pesquisa acadêmica

Instituição de pesquisa	Orçamento de colaboração	Foco na pesquisa
Universidade de Paris-Saclay	€ 1,6 milhão	Mecanismos de doenças fibróticas
Centro de Pesquisa de Inserm	2,3 milhões de euros	Direcionamento molecular

Inventiva S.A. (IVA) - Ansoff Matrix: Market Penetration

You're preparing for the commercial launch of lanifibranor, which means every euro from the recent financing needs to be surgically deployed to capture market share in the MASH space. This market is projected to be worth $48.3 billion globally by the end of 2035, so aggressive penetration in the US and EU is the only way forward.

The November 2025 public offering brought in gross proceeds of approximately €149.0 million, with estimated net proceeds around $161.2 million (€139.3 million). The strategic allocation of this capital directly supports market penetration efforts. You plan to dedicate approximately 80% of these net proceeds toward funding the continuation of the NATiV3 Phase 3 clinical trial and the necessary commercialization activities, with the remaining 20% earmarked for working capital and general corporate purposes. This financing extends the cash runway significantly, now projected until the end of the first quarter of 2027, including the offering proceeds, up from the previous estimate of the end of the third quarter of 2026 before the raise.

To execute this, the immediate action is establishing the commercial infrastructure. This involves building a specialized sales force focused exclusively on high-volume hepatology and endocrinology centers, aligning with the company's decision to stop all other preclinical research to focus solely on lanifibranor. While the exact size of this new force isn't public, the financial commitment is backed by the capital raise, which is essential for securing preferred formulary access with major payers in the US and EU post-approval.

Differentiation hinges on the compelling data from the Phase 2b NATIVE trial, which was the first to demonstrate an effect on the composite histology endpoint of NASH resolution and fibrosis improvement. You need to hammer home these specific statistical achievements when speaking with payers and key opinion leaders:

• NASH resolution with no worsening of fibrosis: 49% for lanifibranor 1200mg/day versus 22% for placebo.
• Improvement of fibrosis by at least one stage with no worsening of NASH: 48% for lanifibranor 1200mg/day versus 29% for placebo.
• Primary endpoint (SAF-A score decrease $\ge 2$ points without worsening fibrosis): 55% for lanifibranor 1200mg/day versus 33% for placebo ($P = 0.007$).

The comparison against placebo for the composite endpoint is particularly strong for market positioning:

Endpoint	Lanifibranor 1200mg/day (%)	Placebo (%)
NASH Resolution + Fibrosis Improvement ($\ge 1$ stage)	35%	9%
SAF-A Score Decrease ($\ge 2$ points) without Fibrosis Worsening	55%	33%

Also, remember the data showing metabolic benefits, which broadens the appeal to the MASH patient population, 42% of whom in the NATIVE trial had type 2 diabetes. Specifically, the 1200mg/day dose reduced glycated hemoglobin (HbA1c) by 0.4% overall (from 6.1% to 5.7%) and by 0.7% in patients with diabetes.

Finance: draft the 13-week cash view incorporating the $161.2 million net proceeds by Friday.

Inventiva S.A. (IVA) - Ansoff Matrix: Market Development

Inventiva S.A. (IVA) is pursuing Market Development by leveraging its existing lanifibranor program into new territories and expanded indications.

The current partnership with Hepalys Pharma, Inc. for Japan and South Korea establishes a framework for expansion across Asia. Inventiva S.A. (IVA) holds a 30% ownership stake in Hepalys Pharma, Inc.. The initial agreement secured an upfront payment of $10 million for Inventiva S.A. (IVA). Tiered royalties on net sales in these territories range from mid double digits to low twenties. The clinical development in Japan began with a Phase 1 trial in February 2025, involving 32 subjects across four cohorts. The diagnosed MASH population in Japan is estimated at up to 2.7% of the population.

Metric	Value	Territory
Upfront Payment	$10 million	Japan & South Korea
Total Potential Milestones	Up to $231 million	Japan & South Korea
Inventiva S.A. (IVA) Ownership	30%	Hepalys Pharma, Inc.
Phase 1 Trial Subjects	32	Japan
Royalty Rate Range	Mid double digits to low twenties	Japan & South Korea

Expanding beyond this initial Asian footprint requires initiating regulatory filings in major Latin American and Middle Eastern markets, contingent upon US/EU approval timelines. The company is actively managing its existing clinical infrastructure, evidenced by its financial commitments. Research and Development (R&D) expenses for the first half of 2025 were €44.9 million. Inventiva S.A. (IVA) reported cash and cash equivalents of €146.7 million as of June 30, 2025, with a cash runway planned until the end of the third quarter of 2026. This financial position is intended to support the ongoing development, which includes the infrastructure use in Europe and North America.

A key element of market development involves expanding the addressable population by exploring lanifibranor's use in MASH patients with compensated cirrhosis. The planned Phase 3 outcome trial for this expanded population is expected to randomize approximately 800 patients. This contrasts with the main cohort of the NATiV3 trial, which randomized 1009 patients with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis. The exploratory cohort of NATiV3 enrolled 410 patients. The US diagnosed MASH population in a 2025 analysis was greater than ~1.5 million, with more than ~315K patients under treater care.

The strategy to minimize direct investment risk in the rest of the world relies on securing a strategic partner for commercialization. The company's recent financing activities show a reliance on capital markets to sustain operations until key data readouts. The second tranche of structured financing brought gross proceeds of €115.6 million in May 2025. Furthermore, a public offering in November 2025 resulted in gross proceeds of approximately $172.5 million (€149.0 million).

• Topline results for the NATiV3 trial are expected in the second half of 2026.
• R&D expenses for the first half of 2025 were €44.9 million.
• Net loss for the first half of 2025 was €175.9 million.
• Cash and cash equivalents as of June 30, 2025, totaled €146.7 million.
• The anticipated receipt of a milestone payment from CTTQ was $10 million.

Inventiva S.A. (IVA) - Ansoff Matrix: Product Development

You're looking at how Inventiva S.A. (IVA) plans to grow by developing new products or significantly improving existing ones. This is the Product Development quadrant of the Ansoff Matrix, and for Inventiva S.A. (IVA), it centers on maximizing the value of their pipeline assets, especially lanifibranor and odiparcil.

The financial foundation for this development is set by their recent cash position. As of September 30, 2025, Inventiva S.A. (IVA) reported cash and cash equivalents of €97.6 million. This follows a period where R&D expenses for the first nine months of 2025 were (€64.6) million. The current cash runway is planned to last until the end of the third quarter of 2026.

A key focus here is re-prioritizing and funding the clinical development of odiparcil for Mucopolysaccharidoses (MPS). This is a move to diversify revenue streams away from the primary focus on MASH. While lanifibranor is in its pivotal Phase 3 NATiV3 trial, with topline results projected for the second half of 2026, odiparcil represents a distinct, rare disease opportunity.

For lanifibranor, the strategy involves expanding its utility. You should allocate a small, dedicated portion of the R&D budget, which was (€64.6) million for the first nine months of 2025, into exploring new indications. Furthermore, developing a fixed-dose combination of lanifibranor with another MASH mechanism of action is planned to aim for enhanced patient outcomes. The Phase 2b NATIVE study already showed an 18% fibrosis placebo-adjusted improvement at 6 months.

The company's proprietary chemistry platform is a core asset for identifying new candidates. This platform is backed by an extensive library of over 240,000 molecules. The goal is to leverage this engine to identify novel small molecules targeting other fibrotic diseases adjacent to MASH. This platform also supports the initiation of pre-clinical work on next-generation pan-PPAR agonists, seeking improved safety or efficacy profiles over existing compounds.

Here's a look at the pipeline focus areas and associated data points:

• Lanifibranor Phase 3 NATiV3 main cohort randomized 1009 patients.
• Lanifibranor intellectual property protection supports market exclusivity through 2041.
• Revenues for the first nine months of 2025 amounted to €4.5 million.
• Odiparcil is being developed for Mucopolysaccharidosis type VI (MPS VI).
• R&D expenses for 9M 2025 were (€64.6) million.

The Product Development strategy relies on advancing these distinct assets concurrently, balancing the near-term readout expectation for lanifibranor with the long-term value creation from earlier-stage programs and platform expansion.

Product Candidate	Indication/Focus	Key Development Metric/Data Point	Target Timeline/Status
Lanifibranor	MASH (Phase 3)	18% fibrosis placebo-adjusted improvement at 6 months (Phase 2b)	Topline results expected H2 2026
Odiparcil	MPS (Lysosomal Storage Disorders)	Diversification of revenue streams	Re-prioritized funding focus
Next-Gen Pan-PPAR Agonists	Pre-clinical	Proprietary library of over 240,000 molecules	Initiate pre-clinical work
Lanifibranor	New Indications/Combination	Cash position as of September 30, 2025: €97.6 million	Invest small portion of R&D budget

The use of the proprietary chemistry platform is intended to identify novel small molecules for other fibrotic diseases, leveraging expertise in compounds targeting nuclear receptors, transcription factors, and epigenetic modulation.

Finance: review Q3 2025 cash burn against the runway projection by next Tuesday.

Inventiva S.A. (IVA) - Ansoff Matrix: Diversification

You're looking at how Inventiva S.A. could pivot beyond its core MASH focus, which is smart given the NATiV3 topline results aren't expected until the second half of 2026. Diversification here means deploying capital and expertise into new areas to smooth out the risk profile inherent in late-stage clinical development.

One path is to re-engage the pre-clinical oncology pipeline. While the pipeline prioritization plan announced in February 2025 led to stopping all pre-clinical research activities, including YAP-TEAD and NR4A1, and a workforce reduction of 50%, a strategic partnership could revive this. Inventiva S.A. already has a pre-clinical pipeline in oncology and maintains royalty-bearing collaborations with Sino Biopharm and Hepalys Pharma, Inc.. A new partnership would need to bring in external funding and expertise to advance these programs without draining internal resources dedicated to lanifibranor.

The financial capacity for a major strategic shift is being built. Inventiva S.A. closed the €116 million second tranche of its Structured Financing in May 2025. As of September 30, 2025, the cash position stood at €97.6 million in cash and cash equivalents, plus €24.7 million in short-term deposits. Furthermore, the company filed for a $300 million Mixed Shelf in October 2025, signaling intent to access significant capital markets funding, which is the kind of move that enables a big acquisition.

Here's a snapshot of the financial foundation as of the third quarter of 2025:

Financial Metric	Amount (as of Sept 30, 2025)	Context/Period
Cash & Short-Term Deposits	€122.3 million (Calculated: €97.6M + €24.7M)	Q3 2025 End
Revenues	€4.5 million	First Nine Months of 2025
Net Cash from Financing	€103.4 million	First Nine Months of 2025
Net Cash Used in Investing	(€25.0) million	First Nine Months of 2025
Cash Runway Estimate	End of Q1 2027	Including November 2025 public offering

Acquiring a clinical-stage asset outside of MASH or rare diseases would be a significant diversification. The existing revenue stream, though small, comes from the pan-PPAR platform technology via the Chia Tai Tianqing Pharmaceutical Group ("CTTQ") license, which provided a $10 million milestone payment (net proceeds of €8.6 million invoiced) and $5 million (€4.3 million) in credit notes in the first nine months of 2025. This demonstrates the value of the platform, which could be leveraged for non-therapeutic licensing to generate non-dilutive revenue, similar to how the CTTQ deal functions, but aimed at different industries.

Establishing a completely new research unit, say in gene therapy, represents the most aggressive diversification strategy, moving into a different modality entirely. This contrasts sharply with the current singular focus on lanifibranor, a novel pan-PPAR agonist. The MASH market itself is projected to reach $48.3 billion by 2035, so the primary focus remains large, but a new unit would be for long-term growth beyond that horizon.

Exploring strategic M&A in the US market for commercial infrastructure is a defintely big move because Inventiva S.A. currently operates with a focus on development, as evidenced by the R&D expenses driving the net cash used in operating activities to (€53.9) million in H1 2025. Gaining US commercial capabilities would mean acquiring sales force, distribution, and marketing infrastructure, which is a capital-intensive step that the recent financing tranches and the $300 million shelf filing are designed to support.

The strategic options for diversification involve leveraging existing financial maneuvers:

• Re-engage pre-clinical oncology via partnership.
• Use cash reserves from the €116 million tranche for acquisition.
• Seek non-therapeutic licensing for the pan-PPAR platform.
• Fund a new research unit with proceeds from the planned $300 million shelf.
• Target US M&A for commercial footprint.

Finance: finalize the pro-forma cash position post-November 2025 offering by Wednesday.